1. Introduction The Court of Justice of the EU (ECJ) has dismissed AstraZeneca's appeal against the Commission's and General Court's findings that the company abused its dominant position under Article 102 TFEU by misusing the patent system and pharmaceutical marketing procedures in order to exclude generic competitors to its ulcer drug Losec from the market and to restrict parallel imports of the drug. The ruling fully supports the Commission's analysis in respect of two novel abuses, which have now firmly been added to the non-exhaustive list of abuses of Article 102 TFEU. 2. Background In June 2005 the EU Commission fined AstraZeneca €60 million for having abused its dominant position under Article 102 TFEU on the market for proton pump inhibitors (PPIs) used for gastro-intestinal
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.